fbpx
The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. logos

CEVR and SCOPE Health Sign a MoU to Develop and Commercialize Novel Product Technologies for the Treatment of Dry Eye and Ocular Surface Conditions

The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have announced the signing of a Memorandum of Understanding (MoU) to establish a collaborative partnership focused on developing innovative technologies for dry eye disease and other ocular surface conditions. By leveraging SCOPE’s knowledge and expertise in eye drop product formulation science, together with CEVR’s extensive experience in ocular drug discovery and delivery translational research, the pair are committed to developing innovative product approaches for doctor and patient unmet ocular surface disease needs.

Professor Ben Thompson, CEO and scientific director of CEVR, remarked, “We are thrilled to collaborate with SCOPE Health Inc., a leading innovator in management solutions for ocular surface diseases. Through this collaboration and SCOPE’s ardent support, engagement in areas such as dry eye management at the practice level and global outreach will increase substantially to deliver tangible change. The research results will advance CEVR’s mission to develop technologies that preserve and enhance vision worldwide. This partnership merges cutting-edge science with formulation and commercialization expertise, paving the way for a transformative solution to support developing technologies that preserve and enhance healthy vision worldwide.”

“Disrupting the status quo and establishing a new standard of care for ocular surface diseases requires collective efforts. Under the leadership of CEVR’s Principal Investigators, Prof. Lyndon Jones, and Dr. Chau-Minh Phan, along with Dr. Howard Ketelson, head of Ideation & Discovery at SCOPE, this collaboration collectively harnesses our expertise’s to develop and commercialize differentiated and clinically valued eyecare products.”

Tom Freyne, CEO, SCOPE Health Inc.

 
Click HERE for the full press release.

Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!

Featured Posts

Optik VOILA January-February 2026 Lanctôt JOS980006_40-petrol-dark-gun

JOS: Titan Bold

JOS Titan Bold is a men’s frame crafted from pure titanium, featuring bevelled edges, masculine matte tones, and beta-titanium temples for durability, flexibility, and refined fit.

Learn More
EQ-based strategies for coping with depression

How to Cope with Depression: An EQ-Based Guide for Professionals

In today’s workplace, stress isn’t just common, it’s constant. Shifting expectations, increased workloads, ever-changing schedules, difficult colleagues, and the pressure to “perform with a smile” can stretch even the highest-achieving professionals thin.

Read more
ClearVision logo

ClearVision Optical Names 2025 Fred Friedfeld Scholarship Recipient

ClearVision Optical recognizes Monica Van Duyne as the 2025 Fred Friedfeld Memorial Scholarship recipient, supporting optometry education.

Read more
Vision Expo new logo

Vision Expo 2026 Marks 40 Years with Unified Annual Event in Orlando

Vision Expo returns to Orlando in March 2026 as a unified annual event, featuring accredited education, new product launches and a 40th anniversary celebration.

Read more
CRO logo image for Research Updates in Optik magazine

Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration

A 2025 review highlights evidence linking vitamins B6, B9 and B12 to reduced risk and slower progression of age-related macular degeneration, with AREDS3 set to explore added benefit.

Read more
Optik VOILA January-February 2026 Lanctôt JOS980006_40-petrol-dark-gun

JOS: Titan Bold

JOS Titan Bold is a men’s frame crafted from pure titanium, featuring bevelled edges, masculine matte tones, and beta-titanium temples for durability, flexibility, and refined fit.

Learn More
EQ-based strategies for coping with depression

How to Cope with Depression: An EQ-Based Guide for Professionals

In today’s workplace, stress isn’t just common, it’s constant. Shifting expectations, increased workloads, ever-changing schedules, difficult colleagues, and the pressure to “perform with a smile” can stretch even the highest-achieving professionals thin.

Read More
ClearVision logo

ClearVision Optical Names 2025 Fred Friedfeld Scholarship Recipient

ClearVision Optical recognizes Monica Van Duyne as the 2025 Fred Friedfeld Memorial Scholarship recipient, supporting optometry education.

Read More
Vision Expo new logo

Vision Expo 2026 Marks 40 Years with Unified Annual Event in Orlando

Vision Expo returns to Orlando in March 2026 as a unified annual event, featuring accredited education, new product launches and a 40th anniversary celebration.

Read More
CRO logo image for Research Updates in Optik magazine

Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration

A 2025 review highlights evidence linking vitamins B6, B9 and B12 to reduced risk and slower progression of age-related macular degeneration, with AREDS3 set to explore added benefit.

Read More
Optik VOILA January-February 2026 Lanctôt JOS980006_40-petrol-dark-gun

JOS: Titan Bold

JOS Titan Bold is a men’s frame crafted from pure titanium, featuring bevelled edges, masculine matte tones, and beta-titanium temples for durability, flexibility, and refined fit.

Learn More
EQ-based strategies for coping with depression

How to Cope with Depression: An EQ-Based Guide for Professionals

In today’s workplace, stress isn’t just common, it’s constant. Shifting expectations, increased workloads, ever-changing schedules, difficult colleagues, and the pressure to “perform with a smile” can stretch even the highest-achieving professionals thin.

Read more
ClearVision logo

ClearVision Optical Names 2025 Fred Friedfeld Scholarship Recipient

ClearVision Optical recognizes Monica Van Duyne as the 2025 Fred Friedfeld Memorial Scholarship recipient, supporting optometry education.

Read more
Vision Expo new logo

Vision Expo 2026 Marks 40 Years with Unified Annual Event in Orlando

Vision Expo returns to Orlando in March 2026 as a unified annual event, featuring accredited education, new product launches and a 40th anniversary celebration.

Read more
CRO logo image for Research Updates in Optik magazine

Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration

A 2025 review highlights evidence linking vitamins B6, B9 and B12 to reduced risk and slower progression of age-related macular degeneration, with AREDS3 set to explore added benefit.

Read more
Optik VOILA January-February 2026 Lanctôt JOS980006_40-petrol-dark-gun

JOS: Titan Bold

JOS Titan Bold is a men’s frame crafted from pure titanium, featuring bevelled edges, masculine matte tones, and beta-titanium temples for durability, flexibility, and refined fit.

Learn More
EQ-based strategies for coping with depression

How to Cope with Depression: An EQ-Based Guide for Professionals

In today’s workplace, stress isn’t just common, it’s constant. Shifting expectations, increased workloads, ever-changing schedules, difficult colleagues, and the pressure to “perform with a smile” can stretch even the highest-achieving professionals thin.

Read more
ClearVision logo

ClearVision Optical Names 2025 Fred Friedfeld Scholarship Recipient

ClearVision Optical recognizes Monica Van Duyne as the 2025 Fred Friedfeld Memorial Scholarship recipient, supporting optometry education.

Read more
Vision Expo new logo

Vision Expo 2026 Marks 40 Years with Unified Annual Event in Orlando

Vision Expo returns to Orlando in March 2026 as a unified annual event, featuring accredited education, new product launches and a 40th anniversary celebration.

Read more
CRO logo image for Research Updates in Optik magazine

Role of B Vitamins in Preventing the Development and Progression of Age-Related Macular Degeneration

A 2025 review highlights evidence linking vitamins B6, B9 and B12 to reduced risk and slower progression of age-related macular degeneration, with AREDS3 set to explore added benefit.

Read more